深圳市泛谷药业

Shenzhen Foncoo Pharmaceutical is a professional pharmaceutical company specializing in the development, registration, and commercialization of drugs for central nervous system (CNS) disorders, particularly mental illnesses. Founded in 1999 and listed on China's New Third Board in 2016, the company has transitioned from a pure product agency model to a collaborative research and self-holding Marketing Authorization Holder (MAH) model. Foncoo's commercial portfolio includes major CNS therapies such as trazodone, milnacipran, bupropion, amisulpride, aripiprazole, and olanzapine, as well as respiratory treatments like salmeterol/fluticasone. The company actively collaborates with global partners, such as Lupin, to introduce high-quality generic and complex generic medicines to the Chinese market.